A panel of experts from the Central Drugs Standard Control Organization (CDSCO) will review the Kovid-19 vaccine of Pfizer, SII and Bharat Biotech tomorrow. According to official sources, the CDSCO committee will meet on Wednesday to review Pfizer, Serum Institute of India and Bharat Biotech applications.
Hyderabad-based cement company Bharat Biotique has sought the immediate use of its Kovid-19 vaccine ‘Kovacsin’. In addition, Pfizer’s Indian branch sought approval from the central drug regulator for its vaccine after such approval was approved in the UK and Bahrain on December 4. On 6 December, the Pune-based Serum Institute of India sought approval for an Oxford Kovid-19 vaccine called Covishield.
Let me tell you, the Hyderabad-based Bharat Biotech Institute is conducting its third phase of the vaccine in about 25 places, including Delhi, Mumbai, Patna and Lucknow.
Budget to be decided after vaccine final: Sitharaman
DCGI has already started processing the application, an official source said. The Covid-19 Subject Expert Panel (SEC) will discuss the applications of Pfizer, Serum Institute of India and Bharat Biotech on December 9 at CDSCO. All of them are seeking emergency approval for their Kovid-19 vaccine. The SEC makes recommendations to DCGI on whether to approve emergency use for vaccine candidates.
India has signed a high rate of corona vaccine, but only 60% of the population has been vaccinated
.
